| __timestamp | Intra-Cellular Therapies, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 17293000 |
| Thursday, January 1, 2015 | 139626 | 26470000 |
| Friday, January 1, 2016 | 93831530 | 28307000 |
| Sunday, January 1, 2017 | 79419009 | 30354000 |
| Monday, January 1, 2018 | 368673 | 32160000 |
| Tuesday, January 1, 2019 | 477121 | 37571000 |
| Wednesday, January 1, 2020 | 1895029 | 39951000 |
| Friday, January 1, 2021 | 8034589 | 50159000 |
| Saturday, January 1, 2022 | 20443000 | 54577000 |
| Sunday, January 1, 2023 | 33745000 | 61940000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. This analysis focuses on Intra-Cellular Therapies, Inc. and Vericel Corporation, two prominent players in the industry. Over the past decade, Vericel Corporation has consistently maintained a higher cost of revenue, peaking at approximately $61.9 million in 2023, a 258% increase from 2014. In contrast, Intra-Cellular Therapies, Inc. experienced significant fluctuations, with a notable spike in 2016, reaching nearly $93.8 million, before stabilizing around $33.7 million in 2023. This disparity highlights the diverse financial strategies and market conditions faced by these companies. As the biotech sector continues to evolve, monitoring these trends provides valuable insights into operational efficiencies and market positioning.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Vericel Corporation
Cost of Revenue Comparison: AstraZeneca PLC vs Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost of Revenue Comparison: BeiGene, Ltd. vs Vericel Corporation
Cost of Revenue Trends: Intra-Cellular Therapies, Inc. vs Dr. Reddy's Laboratories Limited
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Geron Corporation
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated